Publication Name	World Journal of Hepatology
Manuscript ID	19306
Country	China

Received	2015-05-05 10:29
Peer-Review Started	2015-05-05 19:47
To Make the First Decision	2015-06-03 14:56
Return for Revision	2015-06-09 08:46
Revised	2015-09-07 12:12
Second Decision	2015-09-28 14:31
Accepted by Journal Editor-in-Chief	2015-10-01 17:18
Accepted by Executive Editor-in-Chief	2015-10-13 17:08
Articles in Press	2015-10-13 17:08
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-10-15 10:35
Publish the Manuscript Online	2015-10-30 11:57

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Era of direct acting antivirals in chronic hepatitis C: Who will benefit?
Manuscript Source	Invited Manuscript
All Author List	James Fung
Funding Agency and Grant Number
Corresponding Author	James Fung, Consultant, Honorary Clinical Associate Professor, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, 102 Pokfulam Road, Hong Kong, China. jfung@gastro.hk
Key Words	Treatment; Direct acting antivirals; Benefit; Unmet needs; Cirrhosis; Liver transplantation; Chronic hepatitis C
Core Tip	Chronic hepatitis C has become an easily curable disease with new direct acting antivirals (DAAs). However, due to multiple barriers to therapy, only those with highest unmet clinical needs including those with prior treatment failure, cirrhosis, and post-liver transplant, will likely receive therapy. DAAs have been shown to be highly efficacious in these groups.
Publish Date	2015-10-30 11:57
Citation	Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015; 7(24): 2543-2550
URL	http://www.wjgnet.com/1948-5182/full/v7/i24/2543.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i24.2543

Full Article (PDF)	WJH-7-2543.pdf
Full Article (Word)	WJH-7-2543.doc
Manuscript File	19306-Review.docx
Answering Reviewers	19306-Answering reviewers.pdf
Audio Core Tip	19306-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	19306-Conflict-of-interest statement.pdf
Copyright License Agreement	19306-Copyright assignment.pdf
Peer-review Report	19306-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	19306-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	19306-Scientific misconduct check.pdf
Scientific Editor Work List	19306-Scientific editor work list.pdf